RKLB -4.49ASTS -2.11MU 183.5501RHP 0.59MTRN 11.83PSMT 0ESLOY 0MSFT -14.25
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,122.15
+4.89 (0.44%)
as of Jun 25, 2026, 6:14:54 pm Market Open.
218 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is regarded as a leader in the diabetes and weight-loss drug market, particularly with its GLP-1 medications, which are poised for further growth as the company has ramped up production capabilities. Analysts expect strong earnings growth over the next few years, with favorable projections of up to 50% by 2026. While there is some volatility in the stock's performance due to competition and pricing differences, particularly from Novo Nordisk (NVO), Eli Lilly's diversified drug pipeline and financial strength provide a strong foundation. However, many experts suggest waiting for a pullback before entering, as the stock is experiencing high RSI levels and could be overbought. The anticipated introduction of an oral version of its weight-loss drug represents a potential game-changer that could expand market opportunities significantly, reinforcing the bullish outlook for LLY in the long run.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Fair Value
review icon
Similar
Amgen,AMGN
BUY

Eli Lilly & Co.(LLY)

May 09, 2013

50% payout ratio. Drugs are coming off patent. You are buying for yield and low volatility. There are better names in the group but they are in the sweet spot in the market.

Photo of David BurrowsDavid Burrows
No
Unlock Rating
$54.56

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL SELL

Eli Lilly & Co.(LLY)

Apr 05, 2013

Had a very good run. Due for a consolidation period. If you are concerned, take half off the table.

Photo of Keith RichardsKeith RichardsUnlock Rating
$56.48

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Mar 06, 2012
All drug companies are facing the “patent cliff”. (Have a lot of drugs that are coming off patent.) This is pretty well known and all the stocks are cheap. 5% dividend yield. Dividend is safe and you have very good visibility into the cash flows.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$38.64

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Nov 02, 2011
This one is going nowhere fast. Declining earnings. Just had a big drug, Prexus, come off patent, which accounted for 11% of their sales. No new block busters on the horizon. Earnings consensus going from $4.30 to $3.60 next year.
Photo of Don LatoDon Lato
No
Unlock Rating
$37.48

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jun 16, 2011
Industry could be considered a value trap. A large number of large scale pharmas are trading at depressed values because of US health reforms and patents expiring. However this one is in one of the better positions to see itself through this cycle. Have about 70 drugs, mainly in oncology, neuroscience and diabetes that they are working on in their pipeline.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$37.22

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 12, 2010
In the same camp as many of the other big pharmas. Having trouble filling the pot. Patent expirations are taking revenue out. Good cash business with a good dividend of about 5.5%. A value trap.
Photo of Gordon ReidGordon ReidUnlock Rating
$34.78

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Mar 10, 2010
Similar to a lot of Pharma companies in that they have to find some growth. Will have patent expiries in 2011, which will create falling sales. Looks cheap and has a great dividend but it is a shrinking situation.
Photo of Gordon ReidGordon ReidUnlock Rating
$35.34

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Feb 18, 2010
2 issues that face phama stocks: one is health care and what will happen; and two is that the pipeline of fantastic drugs has slowed down. Treat it as a high dividend paying company and not look for huge increases in stock price.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$34.41

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jun 16, 2009
All the pharmaceutical stocks are cheap. He would recommend Johnson & Johnson (JNJ-N) and Merck & Co. (MRK-N) ahead of this one. (See Top Picks.)
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$32.98

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 07, 2009
Pharma is a sector that usually outperforms in times of crisis and in bear markets. They have generally been a good hiding spot. The group will probably lag any uptick in the market. 5.5% dividend.
Photo of Greg A. Taylor, CFA, BBAGreg A. Taylor, CFA, BBAUnlock Rating
$35.85

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Nov 07, 2006
One of the major concerns that pharmacy companies have is patent expiration and generics coming in. Doesn't think they have any major products coming off patents until 2010.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$56.98

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 31, 2006
Hasn't gone anywhere because it hasn't any blockbuster drugs. Has a good pipeline. Demographically, diabetes is set to explode.
Photo of Norman LevineNorman LevineUnlock Rating
$56.01

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Mar 15, 2006
Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$56.97

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 25, 2005
This is a part of the market that's lagging. There has been such a slowdown in the growth rates.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$53.50

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jul 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$56.37

Stock price when the opinion was issued

$1126.05

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 181 to 195 of 205 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -14.25$351.21
PPL.TO 0.7$66.85
CVE.TO -0.09$35
TOU.TO 0.28$60.14
GOOG -5.48$339.56

Today's Top Picks

RKLB -4.49$80.92
ASTS -2.11$65.9
MU 183.55$1232.0601
RHP 0.59$130.36
MTRN 11.83$281.45

Popular Articles

Latest Sell Signals

ATD.TO -0.09$93.67
ITB 0.83$104.15
GLD 3.78$369.7
MU 183.55$1232.0601
MU 183.55$1232.0601

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video